FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient.
We describe a patient who received a living related kidney transplant that worked very well initially but developed oliguria and renal failure within 1 week and required dialysis. Clinical and hemological changes, as well as renal biopsy, confirmed the diagnosis of cyclosporin-induced hemolytic uremic syndrome. The patient did not respond to antirejection therapy or plasma exchange but did respond to the withdrawal of cyclosporin A and the commencement of FK 506.
Abdalla
A H
AH
Department of Nephrology, Riyadh Armed Forces Hospital, Saudia Arabia.
al-Sulaiman
M H
MH
al-Khader
A A
AA
D000328:Adult; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D016559:Tacrolimus / Q000627:therapeutic use*
D016572:Cyclosporine; D016559:Tacrolimus